Meet Dr. Oranus Mohammadi, MD, a board-certified oncologist at The Oncology Institute, who combines expertise with compassionate care to make a difference in the lives of his patients. With a dedication to providing the highest standard of treatment, Mohammadi is committed to guiding patients through their cancer journey with knowledge, empathy, and support. Learn more about her here! #OncologistSpotlight #DrOranusMohammadi #CancerCareExcellence #CompassionateOncology #OncologyInstitute
Targeted Oncology
在线音视频媒体
Cranbury Township，New Jersey 55,880 位关注者
The Community Resource in Targeted Therapies
关于我们
TargetedOnc.com provides content focused on next generation therapeutics and their molecular targets. As the field of oncology continues to trend toward systemic biology and molecular aberrations, the challenge facing many oncologists is staying recent and up-to-date with the future of cancer therapeutics. TargetedOnc.com focuses on the next stage of cancer development, focusing on cutting edge therapies and their biological targets. Content is organized by therapy type, target, peer-reviewed content, and conference coverage.
- 网站
-
https://targetedonc.com
Targeted Oncology的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 2-10 人
- 总部
- Cranbury Township，New Jersey
- 类型
- 上市公司
- 领域
- Oncology、Healthcare Communications、Healthcare、Cancer Research、Targeted Therapies、Community Oncology、Cancer、Cancer Treatment和Oncologists
地点
-
主要
获取路线
2 Clarke Dr
US，New Jersey，Cranbury Township
Targeted Oncology员工
动态
-
Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond. #mmsm | Memorial Sloan Kettering Cancer-Center https://lnkd.in/eUpeQQ8w
-
In an interview with Targeted Oncology, Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma. #mmsm | Mount Sinai Health System https://lnkd.in/gh2R5tfQ
-
-
A phase 2 study evaluating WU-CART-007 for the treatment of adult and pediatric patients with relapsed/refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma is planned to begin in the first quarter of 2025. #leusm #lymsm https://lnkd.in/eTNpGEJj
Study of Novel Off-the-Shelf CAR-T in T-ALL/LBL Launching in 2025
targetedonc.com
-
The #FDA has approved an updated drug labeling for fludarabine phosphate under Project Renewal. https://lnkd.in/gSfWqVFv
FDA Updates Fludarabine Labeling Under Project Renewal Initiative
targetedonc.com
-
The #FDA has granted fast track designation to ALE.P02 for treating patients with CLDN1-positive squamous solid tumors. https://lnkd.in/ewjn7GUK
ALE.P02 Gains FDA Fast Track Status in CLDN1+ Solid Tumors
targetedonc.com
-
In the phase 1 INSIGHT-003 trial, the combination of eftilagimod alpha, pembrolizumab, and chemotherapy showed promising results in terms of overall survival & progression-free survival in metastatic nonsquamous #NSCLC. #lcsm https://lnkd.in/eWqqbFtt
Eftilagimod Alpha Combo Shows Promise in First-Line NSCLC
targetedonc.com
-
The #FDA-cleared Spectral CT 7500 RT, a detector-based computed tomography radiotherapy solution aimed to enhance radiation therapy with spectral 4DCT imaging. https://lnkd.in/eCbBv-kF
FDA Clears Spectral 4DCT for Precision in Radiation Oncology
targetedonc.com
-
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease | #GVHD Memorial Sloan Kettering Cancer-Center https://lnkd.in/epGsdJNa
Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease
targetedonc.com
-
The pivotal phase 3 ECLIPSE trial met its primary end point in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-I&T. #mCRPC #pcsm https://lnkd.in/ey2fkqQA
-